Weight Management

Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.

In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.

Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.

fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.

A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.

Novo Nordisk's top-line phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.

Increasingly, pharmacists are leading the obesity management team.

A single-center study found similar 12-month total weight loss whether or not patients used a glucagon-like peptide-1 (GLP-1) receptor agonist before surgery.

State boards of pharmacy are at the center of this issue and must be positioned and resourced to protect patient safety first.

Real-world data show sustained tirzepatide use offset its cost by 12 months in adults older than 55 years, with fewer hospital and ED visits.

Novo Nordisk's false-advertising case against Eli Lilly turns on GLP-1 dosing—here's the context pharmacists need when patients ask which drug is better.

Gastric emptying delay and glucose-dependent insulin secretion make dietary counseling essential in every GLP-1 receptor agonist encounter.

Adding family-based behavioral treatment to standard care nearly doubled clinically meaningful weight loss in kids in the TEAM UP trial.

A 61,000-woman Danish cohort found overweight or obesity trajectories from 6 years of age tracked with lower odds of childbirth by the mid-20s.

In adults with alcohol use disorder and diabetes or obesity, semaglutide or tirzepatide lowered hospitalization risk across 4 target trial emulations.

An FDA advisory vote boosts access hopes for peptide supporters, but compounding remains illegal pending rulemaking.

Most websites selling GLP-1 receptor agonists prescribed medication with minimal clinical vetting, raising safety concerns pharmacists should be aware of.

The first 2 weeks have produced a specific, recurring set of counter-level problems that have nothing to do with clinical appropriateness.

NHANES data from 1999 to 2023 show obesity, severe obesity, and abdominal obesity climbing across all age groups, with pharmacists positioned to intervene.

Obesity must be treated as the lifelong, chronic condition it is, and pharmacists are essential to making that vision a reality.

Patients with cancer on semaglutide or tirzepatide face hidden drug-drug interactions such as slowed absorption and nausea, requiring antiemetics and pharmacist coordination.

This FAQ breaks down which drugs are covered by the program, who qualifies, how to process claims correctly, and what pharmacists need to know to counsel patients through this landmark shift in obesity drug access.

The new program gives eligible Medicare Part D beneficiaries access to Wegovy, Zepbound, and Foundayo for weight management at a flat $50 co-pay, but early claim-routing errors show pharmacists have a critical role in getting patients across the bridge.

Deanna Horner, PharmD, BCPS, discusses how payers, employers, and health plans can approach GLP-1 coverage by balancing patient access, affordability, clinical value, and long-term cost considerations.

A randomized clinical trial found that both family-based therapy and individual psychoeducational motivational therapy improved symptoms of avoidant/restrictive food intake disorder.